GnRH Agonist and Intrauterine Insemination

Instituto Valenciano de Infertilidad, IVI VALENCIA

Status and phase: Completed; Phase 4

Conditions: Intrauterine Insemination

Treatments: Drug: Tryptorelin

Study type: Interventional

Funder types: Other

Identifiers

NCT00503217

VLC-JB-0205-307-9

Details and patient eligibility

About

The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Sex: Female

Ages: 18 to 38 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Women < 38 years old
• Bilateral tubal patency confirmed by hysterosonography
• Normal ultrasound scan of uterus and ovaries
• Normal day 3 basal hormones
• Motile sperm count after capacitation ≥ 3 mill/ml

Exclusion criteria

• Endometriosis
• Polycystic ovary syndrome
• Uterine disease (polyps, myomas and müllerian diseases)